

1 **Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1**
2 **in critically ill COVID-19 patients: a prospective, multicenter cohort study**

3

4 Nicolas de Prost M.D., Ph.D.^{1,2,3,4}, Etienne Audureau³ M.D., Ph.D.^{5,6}, Antoine Guillon M.D.,
5 Ph.D.⁷, Lynda Handala M.D.⁸, Sébastien Préau M.D., Ph.D.⁹, Aurélie Guigon M.D.¹⁰, Fabrice
6 Uhel M.D., Ph.D.^{11,12}, Quentin Le Hingrat M.D., Ph.D.¹³, Flora Delamaire M.D.¹⁴, Claire
7 Grolhier M.D.¹⁵, Fabienne Tamion M.D., Ph.D.¹⁶, Alice Moisan M.D.¹⁷, Cédric Darreau
8 M.D.¹⁸, Jean Thomin M.D., Ph.D.¹⁹, Damien Contou M.D.²⁰, Amandine Henry M.D.²¹,
9 Thomas Daix M.D., Ph.D.²², Sébastien Hantz M.D., Ph.D.²³, Clément Saccheri M.D.²⁴,
10 Valérie Giordanengo M.D., Ph.D.²⁵, Tàì Pham M.D., Ph.D.^{2,26,27}, Amal Chaghouri M.D.²⁸,
11 Pierre Bay M.D.^{1,2,3,4}, Jean-Michel Pawlotsky M.D., Ph.D.^{3,4,29}, Slim Fourati M.D., Ph.D.
12 ^{3,4,29}, on behalf of the SEVARVIR* investigators

13 **Running title:** JN.1 in severe COVID-19

14 **AFFILIATIONS:**

15 ¹ Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance
16 Publique – Hôpitaux de Paris (AP-HP), Créteil, France

17 ² Groupe de Recherche Clinique CARMAS, Université Paris-Est-Créteil (UPEC), Créteil,
18 France

19 ³ Université Paris-Est-Créteil (UPEC), Créteil, France

20 ⁴ INSERM U955, Team « Viruses, Hepatology, Cancer », Créteil, France

21 ⁵ Department of Public Health, Hôpitaux Universitaires Henri Mondor, Assistance Publique –
22 Hôpitaux de Paris (AP-HP) ;

23 ⁶IMRB INSERM U955, Team CEpiA, Créteil, France

24 ⁷Intensive Care Unit, Tours University Hospital, Research Center for Respiratory Diseases
25 (CEPR), INSERM U1100, University of Tours, Tours, France

26 ⁸INSERM U1259, Université de Tours, Tours, France, CHRU de Tours, National Reference
27 Center for HIV-Associated Laboratory, Tours, France

28 ⁹U1167 – RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au
29 Vieillessement, University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, F-59000 Lille,
30 France

31 ¹⁰Service de virologie, CHU de Lille, F-59000 Lille, France

32 ¹¹ Université Paris Cité, APHP, Hôpital Louis Mourier, DMU ESPRIT, Service de Médecine
33 Intensive Réanimation, Colombes, France

34 ¹² Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker-Enfants
35 Malades (INEM), Paris, France

36 ¹³ Université Paris Cité, IAME INSERM UMR 1137, Service de Virologie, Hôpital Bichat-
37 Claude Bernard, Assistance Publique – Hôpitaux de Paris, Paris, France

38 ¹⁴ CHU Rennes, Maladies Infectieuses et Réanimation Médicale, Rennes, France

39 ¹⁵ Laboratoire de virologie, CHU Rennes, Rennes, France.

40 ¹⁶Service de Médecine Intensive-Réanimation, CHU De Rouen, Rouen, F-76000 Rouen,
41 France.

42 ¹⁷ Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ,
43 DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference
44 Center of HIV, F-76000 Rouen, France

45 ¹⁸ Service de Réanimation médico-chirurgicale, Centre Hospitalier du Mans

46 ¹⁹ Laboratoire de Microbiologie, Centre Hospitalier du Mans

47 ²⁰ Service de Réanimation, Hôpital Victor Dupouy, Argenteuil, France

48 ²¹ Service de Virologie, Hôpital Victor Dupouy, Argenteuil, France

49 ²² Réanimation Polyvalente, INSERM CIC 1435 and UMR 1092, CHU Limoges, Limoges,

50 France

51 ²³ French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene

52 Department, CHU Limoges, F-87000 Limoges, France; INSERM, RESINFIT, U1092, F-

53 87000, Limoges, France

54 ²⁴ Service de Réanimation Médicale, CHU de Nice

55 ²⁵ Laboratoire de Virologie, CHU de Nice

56 ²⁶ Service de Médecine Intensive-Réanimation, Assistance Publique – Hôpitaux de Paris,

57 Hôpital de Bicêtre, DMU 4 CORREVE Maladies du Cœur et des Vaisseaux, FHU Sepsis, Le

58 Kremlin-Bicêtre, France,

59 ²⁷ Inserm U1018, Equipe d'Epidémiologie respiratoire intégrative, CESP, 94807, Villejuif,

60 France

61 ²⁸ Laboratoire de Virologie, Hôpital Paul Brousse, Assistance Publique – Hôpitaux de Paris,

62 Villejuif, France

63 ²⁹ Department of Virology, Hôpitaux Universitaires Henri Mondor, Assistance Publique –

64 Hôpitaux de Paris, Créteil, France

65 *Study Group team members are listed in the Acknowledgments

66 **Corresponding authors:**

67 Prof. Slim Fourati

68 Email: slim.fourati@aphp.fr

69 Tel: +33 1 45 17 81 45

70 Department of Virology, Hôpitaux Universitaires Henri Mondor, Assistance Publique –

71 Hôpitaux de Paris, Créteil, France

72 Prof. N. de PROST

73 Service de Médecine Intensive Réanimation, Hôpital Henri Mondor, Créteil, France

74 E-mail : nicolas.de-prost@aphp.fr

75 Tel: +33 1 45 17 86 37

76

77 **Word count abstract: 100**

78 **Word count text: 1683**

79

80 **ABSTRACT**

81 A notable increase in severe cases of COVID-19, with significant hospitalizations due to the
82 emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. During
83 the study period (November 2022-January 2024), 56 JN.1- and 126 XBB-infected patients
84 were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were
85 more likely to be obese (35.7% vs 20.8%; $p=0.033$) and less frequently immunosuppressed
86 than others (20.4% vs 41.4%; $p=0.010$). JN.1-infected patients required invasive mechanical
87 ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and
88 none received monoclonal antibodies. Day-28 mortality of JN.1-infected patients was 14.6%.

89 **Keywords:** SARS-CoV-2; Omicron; JN.1; Acute Respiratory Failure

90 **Word count of the abstract : 100 words**

91 **BACKGROUND**

92 Following the emergence of the Omicron variant of SARS-CoV-2, several sublineages have
93 co-circulated until the dominance of XBB recombinant variants in early 2023, which were
94 subsequently replaced by a distinct branch of BA.2 named BA.2.86. Compared to XBB and
95 the parental BA.2, the spike protein of BA.2.86 has more than 30 mutations [1]. Initially,
96 BA.2.86 did not dominate other coexisting subvariants until it acquired an additional mutation
97 (i.e., L455S), causing its progeny JN.1 to rapidly increase and become the dominant SARS-
98 CoV-2 variant in several parts of the world. Subsequently, the WHO designated JN.1 as a
99 variant of interest due to its increased transmissibility.

100 Several *in vitro* studies have shown that JN.1 has phenotypic characteristics that confer
101 enhanced *in vitro* fitness. The L455S substitution in the spike protein enhances the ability of
102 the virus to bind to the angiotensin-converting enzyme 2 receptor. JN.1 also appears to be one
103 of the most immune-evading SARS-CoV-2 variants to date, contributing to its increased
104 transmissibility compared to other Omicron sublineages [2].

105 Clinical reports from medical institutions indicate that the risk of serious illness due to JN.1
106 variant infection is low [3]. However, there has been a notable increase in severe cases of
107 COVID-19, with significant hospitalizations due to COVID-19 in late 2023. Importantly, a
108 certain proportion of patients is still admitted to intensive care units (ICUs) for COVID-19-
109 associated acute respiratory failure, but their clinical phenotype and outcomes have changed
110 since the early waves of the pandemic [4,5], and those of patients admitted with severe
111 COVID-19 due to the JN.1 subvariant are currently unknown. This information is critical as it
112 could improve our ability to target individuals who may benefit from more personalized
113 preventive measures, such as frequent vaccination and/or active immunoprophylaxis, as well

114 as tailored therapeutic interventions, including early administration of antivirals in the event
115 of infection.

116 As part of the SEVARVIR study, we have established a prospective French national
117 multicenter cohort focused on patients admitted to ICUs with COVID-19-associated acute
118 respiratory failure. In this specific substudy, our aim is to comprehensively characterize the
119 clinical presentation and outcomes of patients infected with the emerging JN.1 variant and
120 compare them with those infected with sublineages derived from XBB.

121 **METHODS**

122

123 **Study design and patients**

124 The current study is a substudy of the SEVARVIR prospective multicenter
125 observational cohort study. Patients admitted to any of the 40 participating ICUs between
126 November 17, 2022, and January 22, 2024, were eligible for inclusion in the SEVARVIR
127 cohort study (NCT05162508) if they met the following inclusion criteria: age ≥ 18 years,
128 SARS-CoV-2 infection confirmed by a positive reverse transcriptase-polymerase chain
129 reaction (RT-PCR) in nasopharyngeal swab samples, ICU admission for acute respiratory
130 failure (i.e., peripheral oxygen saturation $\leq 90\%$ and need for supplemental oxygen or any type
131 of ventilatory support). Patients with SARS-CoV-2 infection but no acute respiratory failure
132 or with a RT-PCR cycle threshold (Ct) value >32 in nasopharyngeal swabs were not included.
133 The study was approved by the Comité de Protection des Personnes Sud-Méditerranée I (N°
134 EudraCT/ID-RCB: 2021-A02914-37). Informed consent was obtained from all patients or
135 their relatives.

136 Demographics, clinical and laboratory variables were recorded upon ICU admission
137 and during ICU stay. Patients' frailty was assessed using the Clinical Frailty Scale [6]. The

138 severity of the disease upon ICU admission was assessed using the World Health
139 Organization (WHO) 10-point ordinal scale [7], the sequential organ failure assessment
140 (SOFA) score, and the simplified acute physiology score (SAPS) II score. Acute respiratory
141 distress syndrome (ARDS) was defined according to the Berlin definition [8]. The primary
142 clinical endpoint of the study was day-28 mortality.

143 **SARS-CoV-2 variant determination**

144 Full-length SARS-CoV-2 genomes from all included patients were sequenced by
145 means of next-generation sequencing. For mutational pattern analysis at the amino acid level,
146 only high-quality sequences, i.e., sequences covering $\geq 90\%$ of the viral genome and 95% of
147 the spike gene, were considered. Full-length viral genome sequence analysis yielding high
148 coverage have been deposited in Genbank (PP357634 - PP357842).

149 **Statistical Analysis**

150 Descriptive results are presented as mean \pm standard deviation [SD] or median (1st-3rd
151 quartiles) for continuous variables, and as numbers with percentages for categorical variables.
152 Two-sided p-values < 0.05 were considered statistically significant. Unadjusted comparisons
153 between patients infected with two groups of Omicron sublineages (including XBB
154 sublineages, referred to as the “XBB group”, and emerging BA.2.86 sublineages, [parental
155 BA.2.86, JN.1, and JN.3], referred to as the “JN.1 group”) were performed using Chi-squared
156 or Fisher’s exact tests for categorical variables, and ANOVA or Kruskal-Wallis tests for
157 continuous variables, as appropriate.

158 Analyses were performed with Stata V16.1 statistical software (StataCorp, College
159 Station, TX, USA) and R 4.2.0 (R Foundation for Statistical Computing, Vienna, Austria).

160 **RESULTS**

161

162 Between November 17, 2022, and January 22, 2024, 233 patients were admitted to one of the
163 40 participating ICUs and enrolled in the SEVARVIR cohort study. Of these, 126 patients in
164 the “XBB group” and 56 patients in the “JN.1 group” were included in the analysis.

165 No statistically significant differences were observed between patients infected with
166 JN.1 and XBB sublineages with respect to age, gender and frequency of comorbidities.
167 However, patients in the JN.1 group were more likely to be obese ($n=20/56$, 35.7% vs
168 $n=26/125$, 20.8%; $p=0.033$), and had a higher median body mass index (26.4 [22.4-33.4] vs
169 25.0 [21.2-28.7] kg/m^2 ; $p=0.019$). There were also significantly fewer immunosuppressed
170 patients in the JN.1 group than in the XBB group ($n=10/49$, 20.4% vs $n=48/116$, 41.4%;
171 $p=0.010$) (**Table 1**).

172 The proportion of patients who had received at least one dose of SARS-CoV-2 vaccine
173 did not differ significantly between groups, although the median number of doses received
174 was significantly higher in patients from the XBB group (3 [3-4] vs 3 [3-3]; $p=0.019$). The
175 median time from onset of first symptoms to ICU admission was significantly shorter in the
176 JN.1 group than in the XBB group (3 [1-6] vs 5 [3-9]; $p=0.006$). Other variables related to
177 SARS-CoV-2 virological characteristics, including median viral level in the upper respiratory
178 tract measured by cycle threshold in RT-PCR and prevalence of positive SARS-CoV-2 anti-S
179 antibodies at ICU admission, did not differ significantly between groups (**Table 1**).

180 There was no significant difference between the two groups in the severity of illness at
181 ICU admission, as reflected by the SOFA and SAPS II scores and the WHO 10-point ordinal
182 scale (**Table 1**). Invasive mechanical ventilation support was required in 22.0% ($n=40/182$) of
183 patients within 24 hours of ICU admission, with no significant difference between groups. No
184 patient required extracorporeal membrane oxygenation (ECMO) support on ICU admission.
185 Respiratory failure was eventually attributed to SARS-CoV-2 pneumonia without bacterial
186 co-infection in about half of cases in both JN.1 and XBB groups (**Table 2**).

187 During the ICU stay, 32.6% (n=59/181) of patients required invasive mechanical
188 ventilation, with no significant differences between the subgroups. There was also no
189 significant difference between groups regarding the need for other organ support (**Table 2**).
190 Day-28 mortality and ICU length of stay were not significantly different between groups.
191 Regarding COVID-19 management, JN.1-infected patients were treated with dexamethasone
192 significantly more often than their XBB counterparts (n=42/48, 87.5% vs n=66/111, 59.5%;
193 p<0.001). No significant differences between groups were observed in the use of other
194 treatments, including anti-IL-6 antagonists, convalescent plasma and antivirals (**Table 2**).

195 **DISCUSSION**

196

197 The current study is the first to describe the clinical phenotype associated with the
198 newly emerging Omicron sublineage JN.1 in patients with severe COVID-19 requiring ICU
199 admission. Our data provide reassuring evidence that this emerging sublineage does not cause
200 more severe outcomes than XBB variants that emerged and spread earlier in the population.
201 We observed unexpected phenotypic differences, with more frequent obesity and less frequent
202 immunosuppression in patients infected with JN.1, as compared to those infected with XBB
203 sublineages.

204 Recent epidemiologic data have confirmed the increased transmissibility of JN.1. Its
205 proportion of the circulating variants in the US had increased to more than 90% according to
206 nowcast estimates from the US Centers for Disease Control and Prevention (CDC) [9]. In
207 France, JN.1 represented more than 90% of circulating variants, according to the *Santé*
208 *Publique France* report of January 31st, 2024 [10]. In this context, and given the surge in
209 COVID-19 cases during the winter of 2024 [3], obtaining clinical data reporting the clinical
210 phenotype and lethality of patients infected with this subvariant as compared with the
211 previous ones is crucial to inform public health authorities and clinicians managing these

212 patients. Our data provide reassuring evidence regarding the severity of disease associated
213 with JN.1 infection, showing not only a non-significant difference in day 28 mortality
214 compared to patients infected with XBB, but also no significant differences in other
215 outcomes, including the need for invasive mechanical ventilation and length of stay in the
216 ICU.

217 Patients infected with sublineage JN.1 were more likely to be obese and less likely to
218 be immunosuppressed than those infected with XBB in our study. Such a finding was
219 unexpected because immunosuppression has been reported to be the most common
220 comorbidity in COVID-19 patients infected with the Omicron variant since the “ancestral”
221 BA.1 Omicron sublineage [4,11], occurring in almost 50% of cases, and may reflect an
222 inherently less pathogenic variant as reported in a hamster model [12]. On the other hand, the
223 higher prevalence of obesity, a previously reported risk factor for severity with previous
224 SARS-CoV-2 variants, including the ancestral variant, is consistent with previous data
225 reporting obesity as a risk factor for severity [13]. These findings may have important
226 implications for the updated use of pre-exposure monoclonal antibodies use [14] as well as
227 COVID-19 vaccination recommendations. Initial estimates of the updated XBB.1.5 COVID-
228 19 vaccine showed sustained vaccine efficacy against symptomatic JN.1 lineage infection
229 [15]. In terms of ICU management, patients in the JN.1 group received dexamethasone more
230 frequently than their counterparts in the XBB group, possibly because they were less likely to
231 be immunosuppressed. Other aspects of treatment did not differ.

232 Our study has limitations, including a limited sample size in the JN.1 group, which
233 limits our statistical power to perform subgroup analyses and adjust for confounding
234 variables.

235 In conclusion, critically-ill patients with Omicron JN.1 infection showed a different
236 clinical phenotype than patients infected with the earlier XBB sublineage, including more
237 frequent obesity and less immunosuppression. Compared with XBB, JN.1 infection was not
238 associated with significantly different day-28 mortality.

239

240 **Word count of the text : 1683 words**

241 **FOOTNOTE PAGE:**

242 **CONFLICT OF INTEREST STATEMENT:** S.F. has served as a speaker for
243 GlaxoSmithKline, AstraZeneca, MSD, Pfizer, Cepheid and Moderna; J.-M.P. has served as
244 an advisor or speaker for Abbvie, Arbutus, Assembly Biosciences, Gilead and Merck; E.A.
245 has received fees for lectures from Alexion, Sanofi, Gilead and Pfizer. His hospital has
246 received research grant from Pfizer, MSD and Alexion. D.D. served as an advisor for Gilead-
247 Sciences, ViiV Health care, and Merck. N.D.P has served as an advisor or speaker for
248 Moderna and AstraZeneca. Other authors and investigators have no conflict of interest to
249 disclose.

250 **FUNDING STATEMENT:** This work was supported by the EMERGEN consortium—
251 ANRS Maladies Infectieuses Emergentes (ANRS0153). This study has been labeled as a
252 National Research Priority by the National Orientation Committee for Therapeutic Trials and
253 other researches on Covid-19 (CAPNET). The investigators would like to acknowledge
254 ANRS | Emerging infectious diseases for their scientific support, the French Ministry of
255 Health and Prevention and the French Ministry of Higher Education, Research and Innovation
256 for their funding and support.

257 **The current work was not presented previously to a meeting.**

258 **CORRESPONDING AUTHOR:**

259 Correspondence and requests for reprints should be addressed to Prof Fourati : Department of
260 Virology, Hôpitaux Universitaires Henri Mondor, Assistance Publique – Hôpitaux de Paris,
261 Créteil, France ; Email: slim.fourati@aphp.fr; Tel: +33 1 45 17 81 45

262

263 **ACKNOWLEDGMENTS:**

264 The authors would like to thank all staff involved in the study, Dr Pierre-André Natella, Ms.
265 Nolwenn Bombenger for taking care of regulatory aspects, Mr. Léo Graca for taking care of
266 data management, Mr. Mohamed Ader for clinical data abstraction, the nurses and physicians
267 who took care of the patients, the laboratory staff who took care of virological samples and
268 the patients and their family for agreeing to participate in the study. Assistance Publique –
269 Hôpitaux de Paris is the sponsor of the study.

270 The authors would like to thank the **SEVARVIR investigators**: Henri Mondor, Créteil,
271 Medical ICU: Nicolas DE PROST, Pierre BAY, Keyvan RAZAZI, Armand MEKONTSO
272 DESSAP; Henri Mondor, Créteil, Surgical ICU: Raphaël BELLAÏCHE, Lucile PICARD;
273 Henri Mondor Créteil, Virology: Slim FOURATI; Alexandre SOULIER; MéliSSa N'DEBI;
274 Sarah SENG; Christophe RODRIGUEZ; Jean-Michel PAWLOTSKY; Cochin, Paris, Medical
275 ICU: Frédéric PENE; Cochin, Paris, Virology: Anne-Sophie L'HONNEUR ; Saint-Louis,
276 Paris, Medical ICU: Adrien JOSEPH, Elie AZOULAY; Saint-Louis, Paris, Virology: Maud
277 SALMONA; Marie-Laure CHAIX ; Pitié-Salpêtrière, Paris, Medical and cardiac ICU:
278 Charles-Edouard LUYT, David LEVY; Pitié-Salpêtrière, Paris, Medical ICU: Julien
279 MAYAUX ; Pitié-Salpêtrière, Paris, Virology : Stéphane MAROT, Saint-Antoine, Paris,
280 Medical ICU: Juliette BERNIER; Maxime GASPERMENT, Tomas URBINA, Hafid AIT-
281 OUFELLA, Eric MAURY; Saint-Antoine, Paris, Virology : Laurence MORAND-JOUBERT;
282 Djeneba BOCAR FOFANA; Bichat, Paris, Medical ICU: Jean-François TIMSIT; Bichat,
283 Paris, Virology: Diane DESCAMPS, Quentin LE HINGRAT; Tenon, Paris, Medical and
284 Surgical ICU: Guillaume VOIRIOT, Nina DE MONTMOLLIN, Mathieu TURPIN;
285 Avicenne, Bobigny, Medical and Surgical ICU : Stéphane GAUDRY; Avicenne, Bobigny,
286 Virology: Ségolène BRICHLER; Louis Mourier, Colombes, Medical and Surgical ICU:
287 Fabrice Uhel, Damien Roux; Bicêtre, Le Kremlin-Bicêtre, Medical ICU: Tàì Olivier PHAM;

288 Bicêtre, Le Kremlin-Bicêtre, Virology: Amal CHAGHOURI; Raymond Poincaré, Garches,
289 Medical ICU : Nicholas Heming, Djillali Annane; Ambroise Paré, Boulogne, Medical and
290 Surgical ICU: Sylvie Meireles, Antoine Vieillard-Baron; Ambroise Paré, Boulogne, Virology:
291 Elyanne GAULT; Hôpital Marc Jacquet, Melun, Medical ICU: Sébastien Jochmans; Hôpital
292 Marc Jacquet, Melun, Microbiology: Aurélia PITSCH; CH Sud Francilien, Jossigny, ICU:
293 Guillaume CHEVREL, Céline CLERGUE; CH Sud Francilien, Jossigny, Microbiology:
294 Kubab SABAH; CH Victor Dupouy, Argenteuil, ICU: Damien CONTOU; CH Victor
295 Dupouy, Argenteuil, Microbiology: Laurence COURDAVAULT VAGH WEINMANN;
296 Saint-Camille, Bry-sur-Marne, Polyvalent ICU: Malo EMERY; Saint-Camille, Bry-sur-
297 Marne, Microbiology: Claudio GARCIA-SANCHEZ; CHU de Strasbourg, Medical ICU:
298 Ferhat MEZIANI; Louis-Marie JANDEAUX; CHU de Strasbourg, Virology : Samira FAFI-
299 KREMER; Elodie LAUGEL; CHU de Lille, Medical ICU: Sébastien PREAU, Raphaël
300 Favory; CHU de Lille, Virology, Aurélie GUIGNON; CHRU de Nancy, Hôpitaux de Brabois,
301 Medical ICU: Antoine KIMMOUN ; CHRU de Nancy, Hôpitaux de Brabois, Virology:
302 Evelyne SCHVOERER, Cédric HARTARD; Antoine Béclère, Clamart, General ICU: Charles
303 DAMOISEL; Hôpital Européen Georges Pompidou, Paris, Medical ICU: Nicolas BRECHOT;
304 Hôpital Européen Georges Pompidou, Paris, Virology: Hélène PÉRÉ; CHU Tours, Medical
305 ICU: Antoine GUILLON; CHU Tours, Virology : Lynda Handala ; CHU d'Angers, Medical
306 ICU: François BELONCLE; CHU d'Angers, Virology : Françoise LUNEL FABIANI; CHU
307 de Poitiers, Medical ICU : Rémi COUDROY, Arnaud W. THILLE, François ARRIVE,
308 Sylvain LE PAPE, Laura MARCHASSON; CHU de Poitiers, Virology: Luc DEROCHE,
309 Nicolas LEVEQUE; CHU de Rennes, Medical ICU: Jean-Marc Tadié, Flora DELAMAIRE;
310 CHU de Rennes, Virology : Vincent THIBAUT; Claire GROLHIER; CH de Lorient, Medical
311 ICU : Béatrice LA COMBE; CH de Lorient, Microbiology : Séverine HAOUISEE; CHU de
312 Bordeaux, Medical ICU: Alexandre BOYER ; CHU de Bordeaux, Virology: Sonia

313 BURREL; CHU de Rouen, Medical ICU: Fabienne TAMION; Gaetan BEDUNEAU,
314 Christophe GIRAULT, Maximilien GRALL, Dorothée CARPENTIER ; CHU de Rouen,
315 Virology : Alice, MOISAN; Jean-Christophe PLANTIER; CHU de Nantes, Medical ICU :
316 Emmanuel CANET ; CHU de Nantes, Virology : Audrey, RODALLEC, Berthe Marie
317 IMBERT; CHU de Nice, Medical ICU: Clément SACCHERI ; CHU de Nice, Virology:
318 Valérie GIORDANENGO; Marseille Hôpital Nord, Medical ICU : Sami HRAEICH ;
319 Marseille Hôpital Nord, IHU Méditerranée : Pierre-Edouard FOURNIER, Philippe COLSON;
320 CH Le Mans, General ICU: Cédric Darreau; CH Le Mans, Microbiology: Jean THOMIN;
321 CHU de Grenoble, Medical ICU: Anaïs DARTEVEL; CHU de Grenoble, Virology: Sylvie
322 LARRAT; CHU de Saint-Etienne, Medical ICU : Guillaume THIERY; CHU de Saint-
323 Etienne, Virology : Sylvie PILLET; CHU de Montpellier, Medical ICU : Kada KLOUCHE;
324 CHU de Montpellier, Virology : Edouard TUAILLON; CHU de Brest, Medical ICU: Cécile
325 AUBRON; CHU de Brest, Virology : Adissa TRAN, Sophie VALLET; CHU de Dijon,
326 Medical ICU: Pierre-Emmanuel CHARLES; CHU de Dijon, Virology: Alexis DE
327 ROUGEMONT; CHU de Clermont-Ferrand, Medical ICU: Bertrand SOUWEINE; CHU de
328 Clermont-Ferrand, Virology : Cecile HENQUELL; Audrey MIRAND; CHU de Reims,
329 Medical ICU: Bruno MOURVILLIER ; CHU de Reims, Virology: Laurent ANDREOLETTI,
330 Clément LIER; CHU de Caen, Medical ICU : Damien DU CHEYRON; CHU de Caen,
331 Virology : Nefert CANDACE DOSSOU; Astrid VABRET; CHU de Besançon, Medical
332 ICU: Gaël PITON; CHU de Besançon, Virology: Quentin LEPILLER; CHU de Limoges,
333 Medical ICU: Thomas DAIX; CHU de Limoges, Virology: Sébastien HANTZ, Sylvie
334 ROGER

335 **Author's contributions:** N.D.P., E.A., J.M.P., and S.F., designed the study and obtained
336 funding; E.A. performed statistical analyses; N.D.P., A.G., S.P., F.U., F.D., F.T., C.D., D.C.,
337 T.D., C.S., T.P., P.B., included the patient and were responsible for clinical data collection;

338 L.H., A.G., Q.L.H., V.T., A.M., J.T., A.H., S.H., V.G., A.C., and S.F. were responsible of the
339 management of virological samples; J.-M.P., and S.F. were responsible of virological
340 analyses; N.D.P., E.A., and S.F. wrote the first draft of the article; All authors revised and
341 approved the article. The corresponding author attests that all listed authors meet authorship
342 criteria and that no others meeting the criteria have been omitted. N.D.P. and S.F. are the
343 guarantors.

344 REFERENCES

- 345 1. Wang Q, Guo Y, Liu L, et al. Antigenicity and receptor affinity of SARS-CoV-2
346 BA.2.86 spike. *Nature*. **2023**; 624(7992):639–644.
- 347 2. Kaku Y, Okumura K, Padilla-Blanco M, et al. Virological characteristics of the SARS-
348 CoV-2 JN.1 variant. *The Lancet Infectious Diseases*. **2024**; 24(2):e82.
- 349 3. Rubin R. As COVID-19 Cases Surge, Here’s What to Know About JN.1, the Latest
350 SARS-CoV-2 “Variant of Interest.” *JAMA*. **2024**; .
- 351 4. de Prost N, Audureau E, Heming N, et al. Clinical phenotypes and outcomes associated
352 with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. *Nat*
353 *Commun*. **2022**; 13(1):6025.
- 354 5. de Prost N, Audureau E, Préau S, et al. Clinical phenotypes and outcomes associated
355 with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients
356 with COVID-19: a prospective, multicenter cohort study. *Intensive Care Med Exp*. **2023**;
357 11(1):48.
- 358 6. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and
359 frailty in elderly people. *CMAJ*. **2005**; 173(5):489–495.
- 360 7. WHO Working Group on the Clinical Characterisation and Management of COVID-19
361 infection. A minimal common outcome measure set for COVID-19 clinical research.
362 *Lancet Infect Dis*. **2020**; 20(8):e192–e197.
- 363 8. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory
364 distress syndrome: the Berlin Definition. *JAMA*. **2012**; 307(23):2526–2533.
- 365 9. CDC. COVID Data Tracker [Internet]. Centers for Disease Control and Prevention. 2020
366 [cited 2024 Feb 7]. Available from: <https://covid.cdc.gov/covid-data-tracker>
- 367 10. SPF. Infections respiratoires aiguës (grippe, bronchiolite, COVID-19). Bulletin du 31
368 janvier 2024. [Internet]. [cited 2024 Feb 7]. Available from:
369 [https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-national/infections-respiratoires-aigues-grippe-bronchiolite-covid-19-.-bulletin-du-31-janvier-2024)
370 [respiratoires/grippe/documents/bulletin-national/infections-respiratoires-aigues-grippe-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-national/infections-respiratoires-aigues-grippe-bronchiolite-covid-19-.-bulletin-du-31-janvier-2024)
371 [bronchiolite-covid-19-.-bulletin-du-31-janvier-2024](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-national/infections-respiratoires-aigues-grippe-bronchiolite-covid-19-.-bulletin-du-31-janvier-2024)
- 372 11. Vieillard-Baron A, Flicoteaux R, Salmona M, et al. Omicron Variant in the Critical Care
373 Units of Paris Metropolitan Area The Reality Research Group. *Am J Respir Crit Care*
374 *Med*. **2022**; .
- 375 12. Tamura T, Mizuma K, Nasser H, et al. Virological characteristics of the SARS-CoV-2
376 BA.2.86 variant. *Cell Host & Microbe* [Internet]. **2024** [cited 2024 Feb 6]; . Available
377 from: <https://www.sciencedirect.com/science/article/pii/S1931312824000052>
- 378 13. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-
379 related death using OpenSAFELY. *Nature*. **2020**; 584(7821):430–436.

- 380 14. Yang S, Yu Y, Xu Y, et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy
381 immune pressure. *The Lancet Infectious Diseases*. **2024**; 24(2):e70–e72.
- 382 15. Link-Gelles R. Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-
383 19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to
384 Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing
385 Community Access to Testing Program, United States, September 2023–January 2024.
386 *MMWR Morb Mortal Wkly Rep* [Internet]. **2024** [cited 2024 Feb 7]; 73. Available from:
387 <https://www.cdc.gov/mmwr/volumes/73/wr/mm7304a2.htm>

388

389

390 **Table 1.** Clinical and biological characteristics of the 182 patients with severe SARS-CoV-2 infection at the
 391 time of their intensive care unit admission according to the infecting SARS-CoV-2 “sublineage groups”
 392 (XBB vs JN.1 group).

	Data available	All patients N=182	XBB group N=126	JN.1 group N=56	p-value
<i>Demographics and comorbidities</i>					
Sex, females	182	67 (36.8%)	50 (39.7%)	17 (30.4%)	0.23
Age, years	182	70.7 [62.9;76.2]	71.1 [63.2;75.9]	69.5 [62.4;76.8]	0.74
Diabetes	165	61 (37.0%)	41 (35.3%)	20 (40.8%)	0.51
Obesity	181	46 (25.4%)	26 (20.8%)	20 (35.7%)	0.033
Body mass index, kg/m ²	181	25.5 [21.8;30.1]	25.0 [21.2;28.7]	26.4 [22.5;33.2]	0.035
Chronic heart failure	164	27 (16.5%)	16 (13.9%)	11 (22.4%)	0.18
Hypertension	165	96 (58.2%)	65 (56.0%)	31 (63.3%)	0.39
Chronic respiratory failure ^a	165	45 (27.3%)	31 (26.7%)	14 (28.6%)	0.81
Chronic renal failure ^b	165	35 (21.2%)	25 (21.6%)	10 (20.4%)	0.87
Cirrhosis	165	3 (1.8%)	2 (1.7%)	1 (2.0%)	>0.99
Immunosuppression	165	58 (35.2%)	48 (41.4%)	10 (20.4%)	0.010

Immunosuppression	None	164	107 (65.2%)	68 (58.6%)	39 (81.3%)	0.059
	Solid organ transplant		11 (6.7%)	9 (7.8%)	2 (4.2%)	
	Onco-hematological malignancies		27 (16.5%)	23 (19.8%)	4 (8.3%)	
	Others ^c		19 (11.6%)	16 (13.8%)	3 (6.3%)	
Number of comorbidities ^d		166	2.00 [1.00;3.00]	2.00 [1.00;3.00]	2.00 [1.00;3.00]	0.46
Clinical frailty scale		179	3.00 [2.00;4.00]	3.00 [2.00;5.0]	3.00 [2.00;4.00]	0.59
<i>SARS-CoV-2 infection and Vaccination</i>						
Previous SARS-CoV-2 infection		145	26 (17.9%)	19 (19.4%)	7 (14.9%)	0.51
SARS-CoV-2 vaccination		148	123 (83.1%)	83 (79.8%)	40 (90.9%)	0.10
Number of doses among vaccinated		111	3.00 [3.00;4.00]	3.00 [3.00;4.00]	3.00 [3.00;3.00]	0.020
Last dose - ICU admission ^e , days		41	554 [265;680]	315 [189;631]	628 [375;691]	0.067
SARS-CoV-2 serology at ICU admission	Unavailable	182	143 (78.6%)	96 (76.2%)	47 (83.9%)	0.52
	Negative ^f		7 (3.8%)	6 (4.8%)	1 (1.8%)	
	Positive		32 (17.6%)	24 (19.0%)	8 (14.3%)	
First symptoms - ICU admission, days		182	5.0 [2.00;8.0]	5.0 [3.00;9.0]	3.00 [1.00;6.0]	0.006
SARS-CoV-2 RNA detection in nasopharyngeal swabs, Ct		142	19.5 [16.0;22.8]	19.0 [16.0;22.0]	20.0 [17.0;23.0]	0.65
<i>Patients severity upon ICU admission and biological features</i>						
WHO 10-point scale		182	6 (6;6)	6 (6;6)	6 (6;7)	0.329

SAPS II score		153	39.0 [30.0;49.0]	39.0 [31.0;49.5]	37.0 [26.3;48.5]	0.37
SOFA score		163	4.00 [3.00;7.0]	4.00 [3.00;7.0]	4.00 [3.50;7.0]	0.42
PaO ₂ /FiO ₂ ratio, mmHg		177	138 [92.9;197]	131 [93.0;193]	146 [92.0;211]	0.60
ARDS criteria		177	137 (77.4%)	94 (77.0%)	43 (78.2%)	0.87
Arterial lactate level, mM		161	1.50 [1.10;2.20]	1.55 [1.10;2.20]	1.50 [1.10;2.20]	0.98
Blood leukocytes, G/L		176	9.3 [5.9;14.7]	8.9 [4.80;13.4]	10.7 [7.6;17.0]	0.019
Blood lymphocytes, G/L		152	0.50 [0.30;1.10]	0.50 [0.30;0.80]	0.60 [0.40;1.60]	0.052
Blood platelets, G/L		175	204 [139;276]	195 [129;280]	212 [165;273]	0.24
Serum urea level, mM		174	9.0 [6.0;15.0]	9.0 [6.0;14.0]	9.0 [5.8;17.0]	0.87
Serum creatinine level, μM		178	95.5 [65.0;158]	93.5 [61.8;159]	97.0 [69.0;153]	0.47
Bacterial coinfection		181	49 (27.1%)	29 (23.0%)	20 (36.4%)	0.063
Thoracic CT-scan						
Pulmonary embolism		181	10 (5.5%)	5 (4.0%)	5 (8.9%)	0.29
Lung parenchyma involvement, %		60	50.0 [25.0;66.3]	45.0 [25.0;64.3]	50.0 [26.3;68.8]	0.42
Oxygen/ventilatory support	Oxygen	182	33 (18.1%)	24 (19.0%)	9 (16.1%)	0.68
	High flow oxygen		76 (41.8%)	55 (43.7%)	21 (37.5%)	
	NIV/C-PAP		33 (18.1%)	22 (17.5%)	11 (19.6%)	
	Invasive MV		40 (22.0%)	25 (19.8%)	15 (26.8%)	
ECMO		182	0 (0.0%)	0 (0.0%)	0 (0.0%)	-

Vasopressor support	177	30 (16.9%)	20 (16.4%)	10 (18.2%)	0.77
---------------------	-----	------------	------------	------------	------

393
394
395
396
397
398
399
400
401
402
403

Results are N(%), means (\pm standard deviation) or medians (interquartile range). ^arequiring long-term oxygen treatment; ^bdefined as glomerular filtration rate < 60 mL/min/1.73m² ^cincludes HIV infection, long-term corticosteroid treatment, and other immunosuppressive treatments; ^dinclude diabetes, obesity, chronic heart, renal and respiratory failure, hypertension, cirrhosis, and immunosuppression; ^etime lag between the last vaccination dose and ICU admission; ^fdefined as < 30 Binding Antibody Units (BAU)/mL; ARDS: acute respiratory distress syndrome; ICU: intensive care unit; Ct: cycle threshold; WHO: World Health Organization; SOFA: Sequential Organ Failure Assessment; SAPS II: Simplified Acute Physiology Score II; NIV: non-invasive ventilation; C-PAP: continuous-positive airway pressure; MV: mechanical ventilation; ECMO: extracorporeal mechanical ventilation; Two-tailed p-values come from unadjusted comparisons using Chi square or Fisher's exact tests for categorical variables, and t-tests or Mann-Whitney tests for continuous variables, as appropriate. No adjustment for multiple comparisons was performed; **Bolded** p-values are significant at the p<0.05 level.

404
405
406

Table 2. Intensive care management and outcomes of patients with severe SARS-CoV-2 infection (n=182) during their intensive care unit stay according to the SARS-CoV-2 infecting “sublineage groups” (XBB vs JN.1 group).

	Data available	All patients N=182	XBB group N=126	JN.1 group N=56	p-value
Invasive MV	181	59 (32.6%)	43 (34.1%)	16 (29.1%)	0.51
Prone positioning	170	32 (18.8%)	26 (21.7%)	6 (12.0%)	0.14
MV duration, days	56	8.0 [3.75;12.3]	8.0 [4.0;14.0]	4.0 [3.0;9.0]	0.16
Live-ventilator free days at day 28	173	28.0 [15.0;28.0]	28.0 [0.0;28.0]	28.0 [23.3;28.0]	0.22
ECMO support	181	1 (0.6%)	0 (0.0%)	1 (1.8%)	0.30
Vasopressor support	181	49 (27.1%)	38 (30.2%)	11 (20.0%)	0.16
Renal replacement therapy	181	22 (12.2%)	17 (13.5%)	5 (9.1%)	0.40
Ventilator-acquired pneumonia (among IMV) ^a	59	19 (32.2%)	17 (39.5%)	2 (12.5%)	0.048
CAPA	181	6 (3.3%)	6 (4.8%)	0 (0.0%)	0.18
Dexamethasone	159	108 (67.9%)	66 (59.5%)	42 (87.5%)	<0.001
Tocilizumab	181	22 (12.2%)	14 (11.1%)	8 (14.5%)	0.52

Nirmatrelvir-ritonavir	181	4 (2.2%)	3 (2.4%)	1 (1.8%)	>0.99
Monoclonal antibodies	180	1 (0.6%)	1 (0.8%)	0 (0.0%)	>0.99
Duration of ICU stay, days	158				
All patients	180	6.0 [4.00;13.0]	7.0 [4.00;14.0]	6.0 [3.50;11.0]	0.21
In survivors at day 28 only	136	6.0 [4.00;13.3]	6.0 [4.00;14.0]	6.0 [4.00;11.0]	0.52
Day-28 mortality	171	34 (19.9%)	27 (22.0%)	7 (14.6%)	0.28

407 Results are N (%), means (\pm standard deviation) or medians (interquartile range); MV: mechanical ventilation; ECMO: extracorporeal mechanical ventilation; VAP: ventilator-acquired pneumonia; IMV: invasive

408 mechanical ventilation; CAPA: COVID-19-associated pulmonary aspergillosis; ^a VAP episodes were recorded per definition in patients under IMV since more than 48 hours; Two-tailed p-values come from

409 unadjusted comparisons using Chi square or Fisher's exact tests for categorical variables, and t-tests or Mann-Whitney tests for continuous variables, as appropriate. No adjustment for multiple comparisons was
410 performed; **Bolded** p-values are significant at the $p < 0.05$ level.

